Clinical Trial Update: Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial AHEAD-301 compares apatinib plus docetaxel with docetaxel alone as second-line therapy for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN